Table 3.
Regression‐Adjusted Differences in Mean Outcomes between Treatment and Control Groups by Year of Patient Follow‐Up and Demonstration Phase
| Phase I (April 2002–September 2010) | Phase II (October 2010–December 2014) | |||||
|---|---|---|---|---|---|---|
| First Year of Follow‐up (n = 366) | Second Year of Follow‐up (n = 348) | First Through Third Years of Follow‐up (n = 366) | First Year of Follow‐up (n = 483) | Second Year of Follow‐up (n = 386) | First Through Third Years of Follow‐up (n = 483) | |
| Regression‐adjusted difference in mean outcomes between treatment and control groups (p‐value) | ||||||
| Annualized hospitalizations, number per person per year (p‐value) | −0.119 (.37) | −0.227 (.11) | −0.206** (.04) | 0.074 (.54) | 0.077 (.59) | 0.069 (.46) |
| Annualized outpatient emergency department visits, number per person per year (p‐value) | −0.210** (.0495) | −0.312* (.053) | −0.254*** (.007) | 0.059 (.60) | −0.027 (.85) | 0.014 (.88) |
| Medicare Part A and B expenditures, dollars per beneficiary per month (p‐value) | ||||||
| Without program fees | −379 (.14) | −245 (.27) | −360** (.048) | −196 (.49) | 293 (.36) | 19 (.93) |
| With program fees | −263 (.30) | −131 (.56) | −244 (.18) | 76 (.79) | 549* (.09) | 280 (.17) |
| Average length of follow‐up | ||||||
| Mean number of eligible follow‐up months (treatment and control) | 11.7 | 10.2 | 29.2 | 11.4 | 10.3 | 24.5 |
Sample sizes are treatment and control groups combined.
*p < .10, **p < .05, ***p < .01.